(Q44310680)

English

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

László Váróczy

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Erika Zilahi

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Agnes Gyetvai

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Béla Kajtár

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Lajos Gergely

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sándor Sipka

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Arpád Illés

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

14 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Pathology and Oncology Research

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

43-48

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Current treatment strategy of diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Prognostic biomarkers in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Mechanism of action and resistance to monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Gene expression profiling in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1007%2FS12253-011-9414-7

21 January 2018

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/21667346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/21667346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21667346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21667346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/21667346

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12253-011-9414-7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44310680&oldid=2206557809"